<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494282</url>
  </required_header>
  <id_info>
    <org_study_id>INCMNSZ</org_study_id>
    <nct_id>NCT04494282</nct_id>
  </id_info>
  <brief_title>The Economic Impact of the Pancreatography in the Endoscopic Treatment of Pancreatic Pseudocysts</brief_title>
  <official_title>The Economic Impact of the Pancreatography in the Endoscopic Treatment of Pancreatic Pseudocysts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic pseudocysts (PP) present as a complication that occurs in 5-15% of acute&#xD;
      pancreatitis and 26-40% of chronic pancreatitis (1-3). To date the endoscopic drainage with&#xD;
      endoscopic ultrasound (EUS) has replace the surgical treatment due to the similar success and&#xD;
      complication rate but with a lower cost and short hospital stay (4-6). Regarding recurrence,&#xD;
      it is important to know the anatomy of the main pancreatic duct (MPD). For this purpose, the&#xD;
      endoscopic retrograde pancreatography (ERP) has been describe as a useful tool. In fact, many&#xD;
      authors perform it before the endoscopic drainage while others wait several weeks after the&#xD;
      drainage (7-9) with similar technical success (5,8). However, there are no studies that&#xD;
      compare the technical difficulty and the total cost between these two approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODS: Random control trial between two groups. Group 1 the ERP will be performed the same&#xD;
      day of the endoscopic drainage of PP. Group 2 the ERP will be performed 6 weeks after the&#xD;
      endoscopic drainage of PP. Each ERP will be performed by an expert in ERP in patients who&#xD;
      fulfilled the Atlanta criteria for PP. The patients will be enrolled and informed consent&#xD;
      will be explained and signed. In those patients who ERP fails, a second attempt will be&#xD;
      performed 6 weeks after the endoscopic drainage of PP (Group 1) or a magnetic resonance&#xD;
      cholangiopancreatography will be performed (Group 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of the pancreatography in the endoscopic treatment of pancreatic pseudocysts</measure>
    <time_frame>6 weeks</time_frame>
    <description>Determine the impact of the timing performing an endoscopic pancreatography in relation of the drainage of pancreatic pseudocyst</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pseudocyst Pancreas</condition>
  <condition>Pancreatic Duct Disorder</condition>
  <arm_group>
    <arm_group_label>Same day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The ERP will be performed the same day of the endoscopic drainage of PP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The ERP will be performed 6 weeks after the endoscopic drainage of PP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic retrograde pancreatography</intervention_name>
    <description>Endoscopic cannulation of main pancreatic duct</description>
    <arm_group_label>Other day</arm_group_label>
    <arm_group_label>Same day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pancreatic pseudocyst that fulfilled the Atlanta Classification&#xD;
&#xD;
          2. Symptomatic pancreatic pseudocyst&#xD;
&#xD;
          3. Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unwilling to participate&#xD;
&#xD;
          2. Absence of duration time of the pancreatography procedure in the record&#xD;
&#xD;
          3. Absence of the number of weeks between the drainage and the pancreatography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Angela Sa√∫l</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Pseudocyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Pseudocyst</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

